SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001831283-24-000004
Filing Date
2024-02-13
Accepted
2024-02-13 07:04:28
Documents
16
Period of Report
2024-02-09
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lian-20240209.htm   iXBRL 8-K 38386
2 EX-99.1 lianbio-pressreleasexstrat.htm EX-99.1 20316
6 image_0.jpg GRAPHIC 85770
  Complete submission text file 0001831283-24-000004.txt   320699

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lian-20240209.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lian-20240209_lab.xml EX-101.LAB 25850
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lian-20240209_pre.xml EX-101.PRE 13581
17 EXTRACTED XBRL INSTANCE DOCUMENT lian-20240209_htm.xml XML 2966
Mailing Address 103 CARNEGIE CENTER DRIVE, SUITE 309 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER DRIVE, SUITE 309 PRINCETON NJ 08540 (609) 486-2308
LianBio (Filer) CIK: 0001831283 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40947 | Film No.: 24622564
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)